
    
      This is a Phase I, single-center, blinded (with respect to dexpramipexole administration),
      randomized, placebo- and active-controlled, 4-period crossover study in approximately 68
      healthy volunteers. This thorough QT/QTc study will be conducted to formally evaluate the
      effect of dexpramipexole on QT prolongation.
    
  